Evidence map›Paper›PMID 32292342›Full record

ArticleFrontiers in pharmacology2020

Pregnenolone Inhibits Osteoclast Differentiation and Protects Against Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss.

Xiaochen Sun, Chenxi Zhang, Huan Guo, Jiao Chen, Yali Tao, Fuxiao Wang, Xixi Lin, Qian Liu, Li Su, An Qin

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Osteoclast Multinucleation: Review of Current Literature.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaochen SunGuangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, China.
Chenxi ZhangInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Huan GuoInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Jiao ChenInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Yali TaoInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Fuxiao WangInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Xixi LinGuangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, China.
Qian LiuGuangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, China.
Li SuInstitute of Translational Medicine, Shanghai University, Shanghai, China.
An QinGuangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteolytic bone disease is characterized by excessive osteoclast bone resorption leading to increased skeletal fragility and fracture risk. Multinucleated osteoclasts formed through the fusion of mononuclear precursors are the principle cell capable of bone resorption. Pregnenolone (Preg) is the grand precursor of most if not all steroid hormones and have been suggested to be a novel anti-osteoporotic agent. However, the effects of Preg on osteoclast biology and function has yet to be shown. Here we examined the effect of Preg on receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclast formation and bone resorption

Indexed as

ERKLPS (lipopolysaccharide)osteoclast (OCs)OVX modelRANKL (receptor activator of nuclear factor kappa-B ligand)

Identifiers

PMID32292342
PMCPMC7135856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.